This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cicek, M. S. Articles by Witte, J. S. Search for Related Content PubMed PubMed Citation Articles by Cicek, M. S. Articles by Witte, J. S.

Vitamin D Receptor Genotypes/Haplotypes and Prostate Cancer Risk

¹ Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio; ² Department of Epidemiology and Biostatistics, University of California, San Francisco, California; and ³ Channing Laboratory, Brigham and Women's Hospital and Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts

Requests for reprints: John S. Witte, Institute for Human Genetics, Department of Epidemiology and Biostatistics, University of California, San Francisco, Room S965, 513 Parnassus, San Francisco, CA 94143-0794. Phone: 415-502-6882; Fax: 415-476-1356. E-mail: wittej{at}humgen.ucsf.edu

The vitamin D receptor (VDR) gene has been associated with prostate cancer, although previous results are somewhat equivocal. To further study this, we did a family-based case-control study (N = 918) of the association between prostate cancer and six common VDR variants: Cdx2, FokI, BsmI, ApaI, TaqI, and the poly-A microsatellite. Looking at each variant alone, only FokI and ApaI were associated with disease. The FokI FF genotype was inversely associated with prostate cancer among men with less advanced disease (i.e., Gleason score <7 and tumor stage <T_2c), where the odds ratio OR was 0.56 [95% confidence interval (95% CI), 0.31-1.01; P = 0.05]. ApaI, carrying one or two copies of the A allele, exhibited a weak inverse association with disease (OR, 0.64; 95% CI, 0.39-1.03; P = 0.06); this association was strengthened in Caucasian men with more advanced disease (OR, 0.44; 95% CI, 0.21-0.93; P = 0.03). We observed inverse associations between disease and the four-locus FBAt haplotype (OR, 0.48; 95% CI, 0.30-0.76; P = 0.002) and the fbaT haplotype (OR, 0.60; 95% CI, 0.38-0.95; P = 0.03; i.e., in comparison with the FbaT haplotype). These were stronger among men with more advanced disease: for FBAt, the OR was 0.31 (95% CI, 0.16-0.61; P = 0.0008); for fbaT, the OR was 0.32 (95% CI, 0.16-0.64; P = 0.001). These observations support a role for VDR variants in prostate cancer risk but suggest that any potential causal variant(s) may reside on the haplotypes reported here. This would help explain the somewhat equivocal results for VDR genotype-level associations with prostate cancer. (Cancer Epidemiol Biomarkers Prev 2006;15(12):2549–52)

This article has been cited by other articles:

				H. M. Ochs-Balcom, M. S. Cicek, C. L. Thompson, T. C. Tucker, R. C. Elston, S. J.Plummer, G. Casey, and L. Li Association of vitamin D receptor gene variants, adiposity and colon cancer Carcinogenesis, September 1, 2008; 29(9): 1788 - 1793. [Abstract] [Full Text] [PDF]